ANI Pharmaceuticals: The Stock Fell While the Business Grew. The Gap Invites Scrutiny.
Three years ago, ANI Pharmaceuticals was losing money on nearly every dollar it brought in. Today...
Viatris: The Business Is Turning, the Price Tag Already Knows It
Six years ago, Pfizer spun out a division of aging branded drugs, Mylan bolted on its...
The World’s Most Recognizable Beverage Brand Is Up 33% in a Year. The Filed Numbers Tell a More Complicated Story.
First, the shape of it Coca-Cola's filed results for the most recent quarter show a business...
Novavax: A Company That Just Turned Profitable Is Priced Like It Might Not Survive
Novavax's 10-K for fiscal year 2025 shows a net margin of 39.2% and earnings per share...
Acadia Pharmaceuticals: A Business Turning Profitable Trades at a Discount to Its Own History
Ten years ago, Acadia Pharmaceuticals had one approved drug, a stock that had just doubled on...
Gilead’s Ledger: A Business Growing Faster Than Its Balance Sheet Suggests
Six years ago, Gilead Sciences was a company with a problem it couldn't quite name. Its...
Bio-Techne at $72.25: The Price That Was Already Agreed Upon
Before anything else Merck KGaA agreed in June to buy Bio-Techne for $73 per share in...
Halozyme: The Royalty Machine Trading at a Premium to Its Own History
Six years ago, Halozyme Therapeutics was a mid-sized biotech with a clever idea and a thin...
Merck Is Printing Money and Losing Money at the Same Time. Both Are True.
A trailing price-to-earnings ratio of 120 sits next to a price-to-sales ratio near its highest point...
A $2.4 Billion Question: What Sarepta’s Filed Numbers Actually Say
The gist of it Sarepta's filed numbers tell a story of a company that briefly turned...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.